Cargando…
Prevalence of renal and bone risk factors among individuals prescribed oral pre-exposure prophylaxis for HIV
OBJECTIVES: The only available oral pre-exposure prophylaxis (PrEP) regimens approved in the United States to prevent HIV infection during the period covered by this study were emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF). Both agents have simil...
Autores principales: | Fields, Sheldon D., Gruber, Joshua, Clue, Jamaal, Rey, Gabriel Gomez, Cuervo, Helena Díaz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922808/ https://www.ncbi.nlm.nih.gov/pubmed/36793391 http://dx.doi.org/10.1016/j.ijregi.2023.01.004 |
Ejemplares similares
-
Prescribing pre-exposure prophylaxis for HIV
por: Bloch, Mark
Publicado: (2020) -
Improving access to pre-exposure prophylaxis for HIV prescribing in a primary care setting
por: Lumsden, Joshua, et al.
Publicado: (2022) -
Perspectives of women prescribed HIV pre-exposure prophylaxis (PrEP)
por: Park, Connie, et al.
Publicado: (2017) -
Healthcare practitioner experiences and willingness to prescribe pre-exposure prophylaxis in the US
por: Leech, Ashley A., et al.
Publicado: (2020) -
2560. Assessing Resident Perspectives on Prescribing Pre-Exposure Prophylaxis for HIV
por: Shallal, Anita, et al.
Publicado: (2019)